ATAI Life Sciences N.V [NASDAQ: ATAI] stock went on an upward path that rose over 14.96% on Tuesday, amounting to a one-week price increase of more than 20.65%.
Over the last 12 months, ATAI stock rose by 321.80%. The one-year ATAI Life Sciences N.V stock forecast points to a potential upside of 50.31. The average equity rating for ATAI stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.20 billion, with 212.24 million shares outstanding and 136.72 million shares in the current float. Compared to the average trading volume of 6.11M shares, ATAI stock reached a trading volume of 22043966 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on ATAI Life Sciences N.V [ATAI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATAI shares is $11.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATAI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for ATAI Life Sciences N.V shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 29, 2025. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $15 to $10. The new note on the price target was released on November 18, 2024, representing the official price target for ATAI Life Sciences N.V stock. Previously, the target price had yet another raise to $6, while Maxim Group analysts kept a Buy rating on ATAI stock.
The Price to Book ratio for the last quarter was 8.28, with the Price to Cash per share for the same quarter was set at 0.45.
ATAI Stock Performance Analysis:
ATAI Life Sciences N.V [ATAI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.65. With this latest performance, ATAI shares gained by 22.76% in over the last four-week period, additionally plugging by 257.32% over the last 6 months – not to mention a rise of 321.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATAI stock in for the last two-week period is set at 76.16, with the RSI for the last a single of trading hit 0.36, and the three-weeks RSI is set at 0.34 for ATAI Life Sciences N.V [ATAI]. The present Moving Average for the last 50 days of trading for this stock 4.18, while it was recorded at 4.95 for the last single week of trading, and 2.36 for the last 200 days.
Insight into ATAI Life Sciences N.V Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and ATAI Life Sciences N.V [ATAI] shares currently have an operating margin of -31987.01% and a Gross Margin at -5.44%. ATAI Life Sciences N.V’s Net Margin is presently recorded at -38852.87%.
ATAI Life Sciences N.V (ATAI) Capital Structure & Debt Analysis
According to recent financial data for ATAI Life Sciences N.V. ( ATAI), the Return on Equity (ROE) stands at -62.43%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -50.86%, reflecting the company’s efficiency in generating profits from its assets. Additionally, ATAI Life Sciences N.V’s Return on Invested Capital (ROIC) is -87.87%, showcasing its effectiveness in deploying capital for earnings.
ATAI Life Sciences N.V (ATAI) Efficiency & Liquidity Metrics
Based on ATAI Life Sciences N.V’s (ATAI) latest financial statements, the Debt-to-Equity Ratio is 0.06%, indicating its reliance on debt financing relative to shareholder equity.
ATAI Life Sciences N.V (ATAI) Efficiency & Liquidity Metrics
From an operational efficiency perspective, ATAI Life Sciences N.V. (ATAI) effectively leverages its workforce, generating an average of -$2381481.48 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.02% and a Quick Ratio of 4.02%, indicating strong ability to cover short-term liabilities.
ATAI Stock EPS
With the latest financial reports released by the company, ATAI Life Sciences N.V posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.16/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATAI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ATAI Life Sciences N.V go to 19.14%.
ATAI Life Sciences N.V [ATAI] Institutonal Ownership Details
There are presently around $39.80%, or 43.13%% of ATAI stock, in the hands of institutional investors. The top three institutional holders of ATAI stocks are: WALLEYE CAPITAL LLC with ownership of 2.76 million shares, which is approximately 1.7226%. MORGAN STANLEY, holding 2.72 million shares of the stock with an approximate value of $$3.62 million in ATAI stocks shares; and MORGAN STANLEY, currently with $$1.74 million in ATAI stock with ownership which is approximately 0.8148%.
